Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00262-006-0237-4.

Title:
In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines | Cancer Immunology, Immunotherapy
Description:
Listeria monocytogenes-based vaccines for HER-2/neu are capable of breaking tolerance in FVB/N rat HER-2/neu transgenic mice. The growth of implanted NT-2 tumors, derived from a spontaneously occurring tumor in the FVB/N HER-2/neu transgenic mouse, was significantly slower in these mice following vaccination with a series of L. monocytogenes-based vaccines for HER-2/neu. Mechanisms of T cell tolerance that exist in these transgenic mice include the absence of functional high avidity anti-HER-2/neu CD8+ T cells and the presence of CD4+CD25+ regulatory T cells. The in vivo depletion of these regulatory T cells resulted in the slowing in growth of tumors even without the treatment of mice with an anti-HER-2/neu vaccine. The average avidities of responsive CD8+ T cells to six of the nine epitopes in HER-2/neu we examined, four of which were identified in this study, are shown here to be of a lower average avidity in the transgenic mice versus wild type FVB/N mice. In contrast, the average avidity of CD8+ T cells to three epitopes that showed the lowest avidity in the wild-type mice did not differ between wild type and transgenic mice. This study demonstrates the ability of L. monocytogenes-based vaccines to impact upon tolerance to HER-2/neu in FVB/N HER-2/neu transgenic mice and further defines some of the aspects of tolerance in these mice.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Education
  • Science
  • Health & Fitness

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

We donโ€™t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {๐Ÿ”}

pubmed, google, scholar, cas, article, cancer, herneu, mice, immunol, cell, cells, transgenic, tolerance, breast, paterson, tumor, res, regulatory, fvbn, immune, listeria, vaccine, human, mouse, vaccines, vaccination, access, antitumor, immunity, immunotherapy, avidity, epitopes, med, mammary, jaffee, university, pennsylvania, privacy, cookies, content, response, induced, monocytogenesbased, singh, tumors, cdcd, epitope, int, disis, murine,

Topics {โœ’๏ธ}

antigen co17-1a/ga733 encoded lm-llo-ny-eso-1 prior month download article/chapter e6/e7-transgenic mice human papilloma virus-16 listeria monocytogenes-based vaccines anti-tumor immune responses related subjects mhcโ€“peptideโ€“tcr complex antigen-specific antibodies elicited encode tumor-specific antigens early-stage breast cancer dominant regulatory t-cell 2/neu protein-specific antibody therapeutic t-cell responses article cancer immunology monocytogenes-based vaccines cd8+ t-cell epitopes murine mhc class monoclonal antibodies specific wild-type mice full article pdf h-2l genes arose listeria monocytogenes enhances article singh murine mammary gland advanced colorectal cancer 2/neu mhc class privacy choices/manage cookies antitumor immune response human breast cancer antigen-specific immunotherapy monoclonal antibodies reactive her2 dna delivered e7 induce qualitatively yvonne paterson wishes existent t-cell central tolerance limit human colorectal cancer antitumor activity adenovirus inhibits growth reveals subdominant epitopes wild type primary systemic therapy zhen-kun pan functional effects high-avidity cd8 active-specific immunotherapy disis ml spontaneously occurring tumor

Questions {โ“}

  • Lenahan C, Dennis C, Isakovich NV, Pories SE (2005) Breast cancer: whatโ€™s HER-2/neu got to do with it?

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines
         description: Listeria monocytogenes-based vaccines for HER-2/neu are capable of breaking tolerance in FVB/N rat HER-2/neu transgenic mice. The growth of implanted NT-2 tumors, derived from a spontaneously occurring tumor in the FVB/N HER-2/neu transgenic mouse, was significantly slower in these mice following vaccination with a series of L. monocytogenes-based vaccines for HER-2/neu. Mechanisms of T cell tolerance that exist in these transgenic mice include the absence of functional high avidity anti-HER-2/neu CD8+ T cells and the presence of CD4+CD25+ regulatory T cells. The in vivo depletion of these regulatory T cells resulted in the slowing in growth of tumors even without the treatment of mice with an anti-HER-2/neu vaccine. The average avidities of responsive CD8+ T cells to six of the nine epitopes in HER-2/neu we examined, four of which were identified in this study, are shown here to be of a lower average avidity in the transgenic mice versus wild type FVB/N mice. In contrast, the average avidity of CD8+ T cells to three epitopes that showed the lowest avidity in the wild-type mice did not differ between wild type and transgenic mice. This study demonstrates the ability of L. monocytogenes-based vaccines to impact upon tolerance to HER-2/neu in FVB/N HER-2/neu transgenic mice and further defines some of the aspects of tolerance in these mice.
         datePublished:2006-11-28T00:00:00Z
         dateModified:2006-11-28T00:00:00Z
         pageStart:927
         pageEnd:938
         sameAs:https://doi.org/10.1007/s00262-006-0237-4
         keywords:
             Listeria monocytogenes
            CD8+ T cell epitopes
            HER-2/neu
            Tolerance
            Vaccines
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig5_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Reshma Singh
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yvonne Paterson
               affiliation:
                     name:University of Pennsylvania
                     address:
                        name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines
      description: Listeria monocytogenes-based vaccines for HER-2/neu are capable of breaking tolerance in FVB/N rat HER-2/neu transgenic mice. The growth of implanted NT-2 tumors, derived from a spontaneously occurring tumor in the FVB/N HER-2/neu transgenic mouse, was significantly slower in these mice following vaccination with a series of L. monocytogenes-based vaccines for HER-2/neu. Mechanisms of T cell tolerance that exist in these transgenic mice include the absence of functional high avidity anti-HER-2/neu CD8+ T cells and the presence of CD4+CD25+ regulatory T cells. The in vivo depletion of these regulatory T cells resulted in the slowing in growth of tumors even without the treatment of mice with an anti-HER-2/neu vaccine. The average avidities of responsive CD8+ T cells to six of the nine epitopes in HER-2/neu we examined, four of which were identified in this study, are shown here to be of a lower average avidity in the transgenic mice versus wild type FVB/N mice. In contrast, the average avidity of CD8+ T cells to three epitopes that showed the lowest avidity in the wild-type mice did not differ between wild type and transgenic mice. This study demonstrates the ability of L. monocytogenes-based vaccines to impact upon tolerance to HER-2/neu in FVB/N HER-2/neu transgenic mice and further defines some of the aspects of tolerance in these mice.
      datePublished:2006-11-28T00:00:00Z
      dateModified:2006-11-28T00:00:00Z
      pageStart:927
      pageEnd:938
      sameAs:https://doi.org/10.1007/s00262-006-0237-4
      keywords:
          Listeria monocytogenes
         CD8+ T cell epitopes
         HER-2/neu
         Tolerance
         Vaccines
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-006-0237-4/MediaObjects/262_2006_237_Fig5_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Reshma Singh
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yvonne Paterson
            affiliation:
                  name:University of Pennsylvania
                  address:
                     name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:University of Pennsylvania
      address:
         name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Reshma Singh
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Yvonne Paterson
      affiliation:
            name:University of Pennsylvania
            address:
               name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
      name:Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {๐Ÿ”—}(161)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js

CDN Services {๐Ÿ“ฆ}

  • Crossref

4.38s.